For Healthcare Professionals

PrRedemploTM Plozasiran Injection

New Treatment

COMINGSOON

For your adult patients with familial chylomicronemia syndrome (FCS)

Redemplo (plozasiran injection) is indicated as an adjunct to diet to reduce triglyceride levels for adult patients with familial chylomicronemia syndrome (FCS) for whom standard triglyceride lowering therapies have been inadequate.

Once every 3 months dosing

Redemplo is administered as a 25 mg single subcutaneous injection every 3 months.

Stay in the know on Redemplo, including availability details

Sign up

Consult the Product Monograph for important information regarding contraindications, warnings, precautions, adverse reactions, interactions, dosing and conditions of clinical use.

Reference: REDEMPLO Product Monograph. Arrowhead Pharmaceuticals. January 2, 2026.

Are you a Canadian healthcare professional (HCP)?

Meet Redemplo

Enter the following details to stay in the know on Redemplo

Invalid or incomplete information. Please try again.

Are you sure you want to leave this site?

Continue